---
figid: PMC2921612__nihms223760f1
figlink: /pmc/articles/PMC2921612/figure/F1/
number: Figure 1
caption: The VHL protein makes a complex with other proteins and targets hypoxia inducible
  factor for ubiquitin-mediated degradation. This is an oxygen-sensitive process;
  when the oxygen level is normoxic, the VHL complex targets HIF and degrades it.
  When there is hypoxia, HIF is not degraded and this causes the transcription of
  a number of genes known to be important in cancer, such as vascular endothelial
  growth factor (VEGF), platelet derived growth factor (PDGF) and transforming growth
  factor α (TGF-α). Knowledge of the VHL/HIF pathway provides the foundation for the
  development of novel therapeutic approaches to the treatment of patients with advanced
  kidney cancer. Five FDA approved agents, sunitinib, sorafenib, temsirolimus, everolimus
  and bevacizumab are currently used in treatment of patients with advanced clear
  cell kidney cancer.() (Adapted from Pfaffenroth, et al.())
pmcid: PMC2921612
papertitle: Molecular Diagnosis and Therapy of Kidney Cancer.
reftext: W. Marston Linehan, et al. Annu Rev Med. ;61:329-343.
pmc_ranked_result_index: '80471'
pathway_score: 0.9297863
filename: nihms223760f1.jpg
figtitle: Molecular Diagnosis and Therapy of Kidney Cancer
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2921612__nihms223760f1.html
  '@type': Dataset
  description: The VHL protein makes a complex with other proteins and targets hypoxia
    inducible factor for ubiquitin-mediated degradation. This is an oxygen-sensitive
    process; when the oxygen level is normoxic, the VHL complex targets HIF and degrades
    it. When there is hypoxia, HIF is not degraded and this causes the transcription
    of a number of genes known to be important in cancer, such as vascular endothelial
    growth factor (VEGF), platelet derived growth factor (PDGF) and transforming growth
    factor α (TGF-α). Knowledge of the VHL/HIF pathway provides the foundation for
    the development of novel therapeutic approaches to the treatment of patients with
    advanced kidney cancer. Five FDA approved agents, sunitinib, sorafenib, temsirolimus,
    everolimus and bevacizumab are currently used in treatment of patients with advanced
    clear cell kidney cancer.() (Adapted from Pfaffenroth, et al.())
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFRA
  - PDGFRB
  - PDGFD
  - PDGFB
  - PDGFC
  - KDR
  - XRCC1
  - MTOR
  - PDGFA
  - FLT4
  - ARNTL
  - VEGFD
  - VEGFC
  - ARNT
  - VEGFB
  - HIF1A
  - VEGFA
  - EGFR
  - VHL
  - HIF3A
  - PGF
  - ARNT2
  - FLT1
  - TGFA
  - EPAS1
  - Temsirolimus
  - Cancer
genes:
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: RCC
  symbol: RCC
  source: hgnc_prev_symbol
  hgnc_symbol: XRCC1
  entrez: '7515'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: VHL/HIF
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: TGF-a
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: VHL/HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
